Enfortumab Vedotin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Enfortumab vedotin: From Urothelial Cancer to Leprosy (Top TxGNN Prediction)
One-Sentence Summary
Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate (ADC) carrying an MMAE cytotoxic payload, marketed in Singapore as Padcev. The TxGNN model's top-ranked prediction is leprosy, but no clinical trials and no publications support this prediction. Among the ten predictions, only HER2-positive breast carcinoma has any supporting evidence (1 Phase 2 trial, 5 indirect publications), and that evidence is still indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records (the approved indication text is blank) |
| Predicted New Indication | Leprosy (rank 1); the only prediction with a trial is HER2-positive breast carcinoma (rank 10) |
| TxGNN Prediction Score | 99.53% (leprosy); 98.99% (HER2-positive breast carcinoma) |
| Evidence Level | L5 (leprosy); L4 (HER2-positive breast carcinoma) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Enfortumab vedotin is an antibody-drug conjugate. The antibody binds Nectin-4, a cell-surface protein, and delivers the cytotoxic payload MMAE into the cell. Detailed mechanism-of-action data were not available in the data compiled for this report, so the description above is based on the drug class.
Leprosy. No mechanistic link has been established. The high score is a computational output only, and nothing in the data connects a Nectin-4-targeted cytotoxic ADC to a bacterial infection such as leprosy.
Other top-ranked predictions. The following have no plausible rationale and no supporting evidence:
- Multiple endocrine neoplasia
- Cerebral infarction
- HIV infectious disease
- Homozygous familial hypercholesterolemia
- Two veterinary diseases, infectious bovine rhinotracheitis and malignant catarrh. These share an identical score and are probably knowledge-graph artefacts.
The two infection-related predictions that have publications, cytomegalovirus infection and candidiasis, are linked only to adverse-event reports. One is a case of severe oesophagitis after enfortumab vedotin plus pembrolizumab. The other is a pharmacovigilance (FAERS) analysis of ADC safety signals. These are safety observations, not evidence of therapeutic benefit.
HER2-positive breast carcinoma is the only biologically plausible prediction. Nectin-4 is expressed in a subset of breast cancers, notably triple-negative and some HER2-positive tumours. However, the available literature is mostly about bladder cancer or general ADC reviews. One paper on resistance to HER2-targeting ADCs is only indirectly relevant.
Clinical Trial Evidence
Leprosy has no registered trials. The only trial linked to any prediction is listed below for HER2-positive breast carcinoma.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04225117 | Phase 2 | Active, not recruiting | 329 | EV-202: open-label, multicohort study of enfortumab vedotin in locally advanced or metastatic solid tumours. The primary endpoint is objective response rate. No results were available, and breast-specific cohort data cannot be confirmed. |
Literature Evidence
Leprosy has no related literature. The publications below are those linked to HER2-positive breast carcinoma, plus the two adverse-event reports linked to infection predictions.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40614854 | 2025 | Preclinical study | Cancer Letters | Polyploid giant cancer cells mediate resistance to HER2-targeting ADCs (indirect relevance) |
| 32315240 | 2020 | Review | ASCO Educational Book | Novel targets and payloads for ADCs in cancer therapy |
| 42480966 | 2026 | Review | Cancer Letters | ADCs against multidrug-resistant cancers: patient selection, payloads, linkers |
| 41654096 | 2026 | Review | Crit Rev Oncol Hematol | Real-world evidence synthesis for 10 recently approved oncology drugs |
| 41384708 | 2026 | Review | Histopathology | Molecular pathology of bladder cancer |
| 42647281 | 2026 | Case report | Reports (MDPI) | Severe ulcerative oesophagitis after enfortumab vedotin plus pembrolizumab (adverse event; linked to the CMV prediction) |
| 41341429 | 2025 | Pharmacovigilance study | Clinical Epidemiology | FAERS risk signals of ADCs in bladder cancer (linked to the candidiasis prediction) |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16502P | PADCEV® 20 mg/vial powder for concentrate for solution for infusion | Lyophilised powder for injection | Not stated in the available records |
| SIN16503P | PADCEV® 30 mg/vial powder for concentrate for solution for infusion | Lyophilised powder for injection | Not stated in the available records |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate with a cytotoxic payload (MMAE, a microtubule inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; standard monitoring would normally include CBC, liver and renal function, and blood glucose |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
Drug Interactions: The interaction screen returned 100 interactions in total. The first 20 listed include one Major interaction, clarithromycin, and several Moderate ones, mainly with antidiabetic drugs. Examples are metformin, pioglitazone, glimepiride, glipizide, glyburide, and the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Also listed are the DPP-4 inhibitors and GLP-1 agonists such as saxagliptin, linagliptin, exenatide and dulaglutide, along with aprepitant. The full list should be reviewed before any use.
For key warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, leprosy, rests on a computational score alone. There are no trials or publications, and no mechanistic link to a Nectin-4-targeted cytotoxic ADC. Evidence for the other predictions is either absent or limited to adverse-event reports. HER2-positive breast carcinoma is the only plausible lead (L4, research question) but depends on unpublished cohort results.
To proceed, the following is needed:
- Breast-cancer-specific results from the EV-202 trial (NCT04225117), and Nectin-4 expression data in HER2-positive tumours
- Mechanism-of-action data and the approved indication text from the Singapore package insert
- Package insert warnings and contraindications, which are required for safety screening
- Route and formulation compatibility assessment
- Review of the full interaction list, particularly the major interaction with clarithromycin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.